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Abstract
Background: The rate of decline in forced expiratory volume in 1 second (FEV1) is representative of the natural
history of COPD. Sparse information exists regarding the associations between the magnitude of annualised loss of
FEV1 with other endpoints.
Methods: Retrospective analysis of UPLIFT
® trial (four-year, randomized, double-blind, placebo-controlled trial of
tiotropium 18 μg daily in chronic obstructive pulmonary disease [COPD], n = 5993). Decline of FEV1 was analysed
with random co-efficient regression. Patients were categorised according to quartiles based on the rate of decline
(RoD) in post-bronchodilator FEV1. The St George’s Respiratory Questionnaire (SGRQ) total score, exacerbations and
mortality were assessed within each quartile.
Results: Mean (standard error [SE]) post-bronchodilator FEV1 increased in the first quartile (Q1) by 37 (1) mL/year.
The other quartiles showed annualised declines in FEV1 (mL/year) as follows: Q2 = 24 (1), Q3 = 59 (1) and Q4 =
125 (2). Age, gender, respiratory medication use at baseline and SGRQ did not distinguish groups. The patient
subgroup with the largest RoD had less severe lung disease at baseline and contained a higher proportion of
current smokers. The percentage of patients with ≥ 1 exacerbation showed a minimal difference from the lowest
to the largest RoD, but exacerbation rates increased with increasing RoD. The highest proportion of patients with ≥
1 hospitalised exacerbation was in Q4 (Q1 = 19.5% [tiotropium], 26% [control]; Q4 = 33.8% [tiotropium] and 33.1%
[control]). Time to first exacerbation and hospitalised exacerbation was shorter with increasing RoD. Rate of decline
in SGRQ increased in direct proportion to each quartile. The group with the largest RoD had the highest mortality.
Conclusion: Patients can be grouped into different RoD quartiles with the observation of different clinical
outcomes indicating that specific (or more aggressive) approaches to management may be needed.
Trial Registration: ClinicalTrials.gov number, NCT00144339
Keywords: chronic obstructive pulmonary disease, natural history, forced expiratory volume in 1 second, tiotro-
pium, health-related quality of life
Background
An accelerated loss of lung function relative to healthy
individuals is a characteristic feature of chronic obstruc-
tive pulmonary disease (COPD) and has been used to
define the natural history of the disease [1-3]. The semi-
nal publication by Charles Fletcher and Richard Peto
described a rate of loss of forced expiratory volume in 1
second (FEV1) in patients with airflow obstruction
r a n g i n gf r o m3 7±8m L / y e a ri ne x - s m o k e r st o8 0±6
mL/year in heavy smokers (> 15 cigarettes per day),
with an overall effect of 64 ± 3 mL/year [2]. Of note,
the data are based on a relatively small cohort (n = 792)
followed in the 1960s (albeit over a relatively long time
interval of 8 years), the population was restricted to
men and there is no mention of medication washout or
bronchodilator administration preceding spirometry. In
addition, the authors describe a ‘horse-racing’ effect in
which there is an inverse relationship to the degree of
airflow limitation at baseline and rate of subsequent loss
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any medium, provided the original work is properly cited.of FEV1, the ultimate consequence of which, if left una-
bated, would be disability and premature death. The
‘Fletcher-Peto curve’, illustrating the rate of loss over
time, has been widely discussed and displayed in peer-
reviewed publications. However, the associations of dif-
fering magnitudes of loss over time with health out-
comes have not been thoroughly documented.
Furthermore, inferences from several decades ago may
not be currently applicable given the substantial changes
that have occurred in the diagnosis and management of
COPD [1].
The Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT
®) trial is a four-year
randomised, double-blind, placebo-controlled trial of tio-
tropium 18 μg daily in COPD patients who were per-
mitted to use all respiratory medications throughout the
trial other than inhaled anticholinergics [4]. The co-pri-
mary outcomes were the rate of decline in pre- and post-
bronchodilator FEV1.W eh a v et h e r e f o r ec o n d u c t e da
post-hoc analysis of the UPLIFT
® data and have attempted
to categorise patients according to differing rates of
decline in post-bronchodilator FEV1 to document associa-
tions with clinically important health outcomes (i.e.
exacerbations and health-related quality of life [HRQoL]).
Methods
Study Design
The study design of the UPLIFT
® trial has been pre-
viously published [4,5]. In brief, UPLIFT
® was a four-
year, international, randomised, double-blind, placebo-
controlled, clinical trial that evaluated the efficacy and
safety of tiotropium 18 μg daily administered via Handi-
Haler
® (Boehringer Ingelheim GmbH, Ingelheim, Ger-
many) in the treatment of COPD. All patients in the
tiotropium and placebo (control) groups were permitted
to use all respiratory medications other than inhaled
anticholinergics, as prescribed, throughout the trial. A
two- to four-week run-in period was followed by the
randomisation visit, a visit at four weeks, and then clinic
visits every 12 weeks for the duration of the trial. A
washout visit in which patients were asked to administer
ipratropium 40 μg four times daily was scheduled for 30
days following completion of randomised study drug.
The study was approved by ethics committees and
institutional review boards and was conducted in accor-
dance with the Helsinki Declaration. Written informed
consent was obtained from all patients.
Study Population
Men and women who were aged ≥ 40 years, had ≥ 10
pack-year history of smoking and had evidence of air-
flow limitation (defined by a post-bronchodilator FEV1
≤ 70% predicted and an FEV1/forced vital capacity
(FVC) ≤ 0.70) were included. Exclusion criteria included
a history of asthma, pulmonary resection, unstable dis-
ease, recent myocardial infarction and recent hospitalisa-
tion for congestive heart failure. Other criteria are
outlined in previous publications and were designed to
exclude patients who might not reasonably be assumed
to be able to complete the trial or had an underlying
disease that would interfere with the interpretation of
the study results [4,5].
Procedures
Spirometry was performed according to American Thor-
acic Society criteria at baseline, four weeks and every six
months following randomisation [6]. After screening,
spirometry was performed prior to, and following, short-
acting bronchodilator and study drug administration.
Short-acting bronchodilators were administered sequen-
tially (ipratropium bromide four actuations, albuterol
four actuations 60 minutes later) with spirometry being
performed 30 minutes following the last dose. HRQoL
was measured using the St George’s Respiratory Ques-
tionnaire (SGRQ) at baseline and every six months [7].
Exacerbations were recorded on case report forms and
were required to follow a standard definition as follows:
an increase in or the new onset of more than one
respiratory symptom (cough, sputum, sputum purulence,
wheezing or dyspnea) lasting three days or more and
requiring treatment with an antibiotic or a systemic cor-
ticosteroid. All adverse events were recorded throughout
the period of study drug administration. In addition,
investigators were requested to collect vital status infor-
mation on patients who prematurely discontinued study
medication during the four years of the trial.
Data Analysis
Spirometric variables (FEV1, FVC and slow vital capa-
city) and SGRQ were analysed using random-effects
models. The decline of lung function over time was ana-
lysed with random co-efficient regression. Patients were
categorised according to quartiles based on the annual-
ised rate of post-bronchodilator FEV1 decline. As treat-
ment intervention with tiotropium would potentially
interact with the health outcomes measured, the analysis
was stratified by treatment group. Hazard ratios for
exacerbations, hospitalised exacerbations and death were
determined using Cox regression. The numbers of
exacerbations and associated hospitalisations were calcu-
lated using Poisson regression with adjustment for over-
dispersion and treatment exposure. Baseline data were
not included in the FEV1 model.
Results
Demographics
A total of 4964 patients from the total population (n =
5993) had evaluable spirometry for evaluation of rate of
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quartile by treatment group is as follows: Q1 (tiotro-
pium 661, control 580), Q2 (tiotropium 645, control
596), Q3 (tiotropium 627, control 614), Q4 (tiotropium
621, control 620). Overall, the mean (standard error
[SE]) post-bronchodilator FEV1 increased in the first
quartile (Q1) by 37 (1) mL/year (Figure 1). The other
quartiles showed annualised mean (SE) declines in FEV1
(mL/year) as follows: Q2 = 24 (1), Q3 = 59 (1) and Q4
= 125 (2). The corresponding rates for post-bronchodi-
lator FVC were as follows: increase in Q1 = 41 (4),
decreases in Q2, Q3 and Q4 (Q2 = 33 [4], Q3 = 81 [4]
and Q4 = 179 [5]). The baseline characteristics of the
population by quartiles of rate of decline in post-
bronchodilator FEV1 are displayed in Table 1. Approxi-
mately 75% were men with an average age of 64 years.
Overall, age, gender, respiratory medication use at base-
line and SGRQ total score did not appear to distinguish
groups, although the subjects in the highest quartile
tended to be younger and more predominantly male.
The largest rate of decline included the highest propor-
tion of current smokers. Patients with the largest rate of
decline had less severe lung disease on average at base-
l i n ea ss e e nb yF E V 1, FVC and Global Initiative for
Chronic Obstructive Lung Disease (GOLD) stage (Table
2).
Health Outcomes
The proportion of patients with at least one exacerba-
tion over four years showed a minimal difference from
the lowest rate of decline (Q1 = 66.6% [tiotropium] and
73.3% [control]) to the largest rate of decline (Q4 =
73.8% [tiotropium] and 76.6% [control]) (Figure 2A).
However, in general, there was an increased rate of
exacerbations with increasing rate of decline in post-
bronchodilator FEV1 (Table 3). The highest proportion
of patients with at least one hospitalised exacerbation
was in the group with the largest rate of decline (Q1 =
19.5% [tiotropium] and 26% [control], Q4 = 33.8% [tio-
tropium] and 33.1% [control]) (Figure 2B). Overall, the
time to the first exacerbation and first hospitalised
exacerbation was shorter with increasing rate of decline
in FEV1 quartiles, although results were somewhat
inconsistent, especially for patients in the third quartile
in the control group (Table 4).
The annualised rate of decline in the SGRQ total
score increased linearly with each quartile increase in
the post-bronchodilator decline in FEV1 (Figure 3). The
range was from an improvement over time in Q1 (con-
trol 0.55 [0.19] units, tiotropium 0.24 [0.17] units) to
the largest worsening in the Q4 group (control 2.87
[0.19] units, tiotropium 2.66 [0.18] units). The pattern
Figure 1 Annualised RoD in pre- and post-bronchodilator FEV1 by quartiles for tiotropium and control groups. Abbreviations: RoD, rate
of decline; FEV1, forced expiratory volume in 1 second.
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in Figure 4.
Mortality
There appeared to be no distinguishing pattern of risk
of a fatal event among the first three quartiles (Q1, Q2,
Q3); however, the group with the largest rate of FEV1
decline (Q4) had the highest overall mortality rate (Fig-
ure 5). For all of the hazard ratios, the 95% confidence
intervals included one.
Discussion
The four-year UPLIFT
® trial provided data that per-
mitted examination of associations of the magnitude of
Table 2 Baseline spirometry of the UPLIFT
® study population according to quartiles of RoD in post-bronchodilator
FEV1
Rate of decline quartile
Q1
(n = 1241)
Q2
(n = 1241)
Q3
(n = 1241)
Q4
(n = 1241)
FEV1 (L)
Pre-bronchodilator 1.11 ± 0.40 1.06 ± 0.40 1.09 ± 0.39 1.21 ± 0.39
Post-bronchodilator 1.33 ± 0.44 1.28 ± 0.44 1.32 ± 0.44 1.47 ± 0.42
FEV1 (% predicted)
Pre-bronchodilator 39.7 ± 12.1 39.1 ± 12.0 39.3 ± 12.1 41.4 ± 11.3
Post-bronchodilator 47.6 ± 12.7 47.3 ± 12.8 47.8 ± 12.6 50.0 ± 11.5
FEV1 (% increase)* 22.6 ± 18.7 23.7 ± 17.4 24.1 ± 17.9 23.2 ± 18.2
FVC (L)
Pre-bronchodilator 2.56 ± 0.81 2.51 ± 0.81 2.62 ± 0.79 2.92 ± 0.79
Post-bronchodilator 2.99 ± 0.87 2.97 ± 0.86 3.10 ± 0.83 3.42 ± 0.86
FVC (% predicted)
Pre-bronchodilator 72.7 ± 17.6 73.6 ± 17.6 75.2 ± 18.1 79.0 ± 17.3
Post-bronchodilator 84.9 ± 18.7 87.2 ± 18.3 89.1 ± 19.1 92.7 ± 17.9
GOLD stage (%)
II 45 46 45 54
III 44 43 45 40
IV 91 0 84
*Increase from baseline following ipratropium four actuations and albuterol four actuations.
Values displayed as means ± SD unless otherwise indicated.
Abbreviations: UPLIFT
®, Understanding Potential Long-Term Impacts on Function with Tiotropium; RoD, rate of decline; FEV1, forced expiratory volume in 1
second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation.
Table 1 Baseline characteristics of the UPLIFT
® study population according to quartiles of RoD in post-bronchodilator
FEV1
Rate of decline quartile
Q1
(n = 1241)
Q2
(n = 1241)
Q3
(n = 1241)
Q4
(n = 1241)
Male (%) 77 72 75 80
Age (years) 65 ± 9 65 ± 8 64 ± 8 63 ± 9
Smoking history (%)
Ex-smoker 73 76 71 63
Current smoker 27 24 29 37
Duration of COPD (years) 10 ± 8 10 ± 8 10 ± 8 9 ± 7
Inhaled respiratory drugs (%)
LABA 61 60 62 58
ICS 63 61 60 61
LABA + ICS 50 48 49 47
Anticholinergic 43 44 43 46
SGRQ total score (units) 45 ± 18 45 ± 17 45 ± 17 46 ± 17
Abbreviations: UPLIFT
®, Understanding Potential Long-Term Impacts on Function with Tiotropium; RoD, rate of decline; FEV1, forced expiratory volume in 1
second; COPD, chronic obstructive pulmonary disease; LABA, long-acting b2 agonist; ICS, inhaled corticosteroids; SGRQ, St George’s Respiratory Questionnaire.
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vant health outcomes of exacerbations, HRQoL and sur-
vival [4,5]. In order to examine patterns, the annualised
rate of loss of post-bronchodilator FEV1 was divided
into quartiles. Other than smoking status, demographics
and respiratory medication use appeared to be largely
similar among groups; and the most prominent differ-
ence at baseline was lung function, which appeared to
be least impaired in those with the most rapid loss in
FEV1. In longitudinal analyses, the patterns associated
with quartiles of increasing rate of decline in FEV1 indi-
cated a relationship to an accelerated loss of HRQoL,
increased rate of exacerbations, increased risk of a hos-
pitalised exacerbation and increased risk of death.
COPD is described as a disease of progressive airflow
limitation, for which the most described marker remains
the serial measurement of FEV1 [1]. The publication by
Fletcher and Peto placed FEV1 decline over time at the
forefront of biomarkers that illustrate disease progres-
sion [2]. However, the utility of any biomarker is some-
what dependent on its predictive value or associations
with other clinically important endpoints. In this regard,
there are two main analytic approaches to FEV1, regard-
less of whether it is described as an absolute volume or
as a percentage of predicted normal. The first approach
is the static single-point measurement. While there is a
Figure 2 Incidence of exacerbations according to quartiles of post-bronchodilator FEV1 RoD. Proportion of patients with (A) at least one
exacerbation and (B) at least one hospitalised exacerbation. Abbreviations: FEV1, forced expiratory volume in 1 second; RoD, rate of decline.
Table 3 Number of exacerbations per patient-year
according to post-bronchodilator FEV1 RoD quartiles
Tiotropium Control Rate ratio (tiotropium/control)*
(95% CI)
Q1 0.63 0.80 0.79 (0.69 to 0.91)
Q2 0.64 0.83 0.77 (0.68 to 0.88)
Q3 0.75 0.78 0.96 (0.85 to 1.09)
Q4 0.85 0.91 0.93 (0.82 to 1.06)
*Rate ratio based on Poisson regression with adjustment for overdispersion.
Abbreviations: FEV1, forced expiratory volume in 1 second; RoD, rate of
decline; CI, confidence interval.
Table 4 Time to first exacerbation and first hospitalised
exacerbation according to post-bronchodilator FEV1 RoD
quartiles
Tiotropium Control Hazard ratio(tiotropium versus control)*
(95% CI)
Time to first exacerbation, median month
Q1 19.4 14.6 0.80 (0.70 to 0.92)
Q2 22.4 13.6 0.83 (0.73 to 0.94)
Q3 16.6 16.3 0.97 (0.86 to 1.11)
Q4 14.9 12.7 0.88 (0.78 to 1.01)
Time to first exacerbation leading to hospitalization (first quartile),
month
Q1 NA 39.9 0.72 (0.57 to 0.91)
Q2 47.2 32.5 0.73 (0.59 to 0.90)
Q3 37.0 40.2 1.05 (0.86 to 1.30)
Q4 28.5 26.0 0.98 (0.81 to 1.18)
*Hazard ratio based on Cox regression with treatment, rate of decline quartile,
and rate of decline by treatment interaction as covariates.
Abbreviations: FEV1, forced expiratory volume in 1 second; RoD, rate of
decline; CI, confidence interval.
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ity, the descriptions of which date back several decades
[8,9], composite measures such as the BODE index that
have FEV1 as a part of the measure appear to have
higher predictive values [10]. Additionally, other para-
meters such as comorbidities and serum markers should
continue to be explored for associations with disease
progression. Yet a single measurement of FEV1 is poorly
associated with other health outcomes such as exercise
tolerance and quality of life. This may relate to issues of
a single measurement in a disease that is known to have
substantial day-to-day or week-to-week variability. The
second analytic approach is serial measurements over
time examining the pattern of change (i.e. slope).
Most studies have described FEV1 decline in the
context of the effects of cigarette smoking and cessa-
tion of exposure to cigarette smoke with minimal data
being published on the associations of rate of decline
in FEV1 with other health outcomes [3,11]. The rate of
loss of lung function over time was recently described
in the Towards a Revolution in COPD Health
(TORCH) trial [12]. The authors noted that an
increased rate of decline was associated with more fre-
quent exacerbations [12]. A rapid decline in FEV1 has
been associated with more frequent exacerbations of
COPD in other studies [13,14] and severe exacerba-
tions have been shown to be associated with premature
death [15]. The remaining studies have used FEV1 as
an outcome measure but have not described changes
in FEV1 over time relative to changes over time in
other outcomes [16-19].
Our current population showed that age and gender
did not differ significantly among the quartiles of FEV1
decline. Indeed, it appears that physician’s treatment
patterns, as viewed by concomitant respiratory medica-
tion prescription, also did not distinguish patient groups,
at least as defined by disease severity at baseline (GOLD
stage). Continued smoking did show differences, which
is entirely expected and also provides evidence that the
subgroups are valid [20]. The most rapid loss was
observed in patients who appeared to have somewhat
milder disease, either by absolute FEV1,F E V 1 percent
predicted or FVC. This seems to be somewhat contrary
to the ‘horse-racing’ effect described by Fletcher and
Peto, but may highlight the need for earlier and aggres-
sive intervention in patients with COPD [2]. There may
be several possible explanations for the differences in
our study and that of Fletcher and Peto as follows: (a)
different populations (British coal miners vs. well char-
acterized multinational representation), (b) sample size
(larger in the UPLIFT trial), (c) survival (more likely to
have severe disease in the UPLIFT trial due to advance
in health care), and (d) environmental conditions (coal
miners and likely higher levels of particulate exposure
vs. current air quality standards). A consistency is seen
with recent data that show improvements in outcomes
with long-term pharmacotherapy in GOLD stage II
patients (UPLIFT
® and TORCH), as well as significant
benefit in patients not previously receiving maintenance
respiratory medication [4,21,22].
Certain limitations should be noted. The calculation of
FEV1 decline was only continued while the patient
Figure 3 Annualised decline in SGRQ total score (units/year) according to post-bronchodilator FEV1 RoD quartiles. Abbreviations: SGRQ,
St George’s Respiratory Questionnaire; FEV1, forced expiratory volume in 1 second; RoD, rate of decline.
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mature discontinuation of study drug. Premature dis-
continuation of study drug occurred in more control
patients (45%) than tiotropium patients (36%). However,
there was still substantial exposure to both study drugs
during the trial with multiple measurements over years
in most patients in the current analysis. Suissa describes
the phenomenon of regression to the mean, which cer-
tainly could contribute to our findings; however, the
inclusion of a data point closely following randomisation
(i.e. at 30 days) should limit this [23]. Each treatment
group needs to be considered independently since
between-treatment comparisons are not valid, given that
subgroups are based on outcomes (i.e. rate of decline in
FEV1). Furthermore, there is a bias toward the more
severe COPD patients preferentially in the tiotropium
group continuing to completion, due to the effectiveness
of the intervention, which created unequal groups as the
trial progressed. Nevertheless, the pattern of association
of quartiles to rate of decline in FEV1 can be observed
within both treatment groups.
The study’s strengths included the large sample size,
the rather liberal inclusion criteria, the length of the
trial and the rigorous nature of the data collection. The
latter is particularly true of spirometry, which pre-speci-
fied a stringent protocol and involved standardised
equipment, study specific software and a centralised
review of all measurements.
The current results provide supportive evidence of the
relevance of serial measurements in FEV1 over time. A
rapid loss of lung function appears to identify a group at
Figure 4 SGRQ total score over four years by annualised RoD
in post-bronchodilator FEV1. (A) tiotropium and (B) control
groups. Abbreviations: SGRQ, St George’s Respiratory Questionnaire;
RoD, rate of decline; FEV1, forced expiratory volume in 1 second;
ANOVA, analysis of variance.
Figure 5 Proportion of patients who died during treatment according to post-bronchodilator FEV1 RoD quartiles. Protocol defined
treatment period (1440 days). Data also include those patients who discontinued study drug. Abbreviations: FEV1, forced expiratory volume in 1
second; CI, confidence interval; RoD, rate of decline.
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exacerbations (i.e. hospitalised events), an accelerated loss of
HRQoL and premature mortality. FEV1 measurement is
simple, relatively inexpensive, widely available and well stan-
dardised with published normative values. COPD is a
chronic disease and patients with COPD may be followed
clinically for several decades. Identification of rapid decliners
could be clinically useful since such patients may represent
au n i q u es u b s e to fp a t i e n t sw h orequire aggressive interven-
tions. It is relevant to note that there can be marked hetero-
geneity between individuals regarding the absolute annual
loss of lung function, which will be influenced by their
genetic background and environmental factors.
Identification of patients with the most rapid decline
in lung function, particularly in the early stages of
COPD, would require a study of reproducibility of
FEV1 and its decline in individual patients, possibly at
short intervals (e.g. 3-6 monthly). Before translating to
clinical practice, further research is needed regarding
the reproducibility and patterns of rate of decline in
individual patients. At a minimum, additional research
is required to identify factors, other than continued
exposure to noxious fumes and particulate matter (i.e.
tobacco smoke), such as biomarkers and genetic pat-
terns that can both predict a rapid decline and lead to
novel approaches in treatings u c hp a t i e n t s .A n o t h e r
issue to consider is whether rapid decliners represent a
distinct subset of COPD. In an editorial, Rennard and
Vestbo described an approach in which COPD can be
considered an orphan disease requiring unique
approaches to different forms of the disease [24].
Moreover, in another editorial, Reilly wrote about
COPD being the sum of many small COPDs [25].
Whether this is the case for rapid or slow decliners
remains to be determined.
Conclusion
The current data suggest that patients can be divided
into different rates of decline with the observation of
different clinical outcomes indicating that specific (or
more aggressive) approaches to management are needed.
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